Genentech has received FDA approval of Vabysmo® for the treatment of macular edema due to retinal vein occlusion (RVO) beyond six months. RVO affects over a million Americans and often involves long-term intravitreal therapy to address the chronic nature of the disease. “This label update reinforces our commitment to delivering consistent, long-term solutions for patients [Read More]
Category: Therapies, Treatments, and Procedures
PRIMA System Improves Sight in Individuals With Geographic Atrophy
A study involving participants with geographic atrophy due to dry AMD, has shown that a photovoltaic subretinal implant, combined with glasses that project near-infrared light to the implant, has led to significant improvement in visual acuity in 32 participants. This so-called PRIMA system represents the first eye prosthesis to restore functional sight in people with [Read More]
New Drug Approved for Treatment of Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals, Inc. has announced FDA approval of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). ENCELTO is the First and Only FDA-approved first and only treatment for MacTel. MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients’ quality of [Read More]
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Genentech to Reintroduce Susvimo for People With Wet AMD
The FDA has approved updates to Susvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks. Genentech announced today the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States with wet, or neovascular, age-related [Read More]